市場調查報告書

全球大腸激躁症治療藥市場:各類型(腹瀉型,便秘型,混合型),各產品,各終端用戶—市場機會分析與業界預測(2019年 ̄2026年)

Irritable Bowel Syndrome Treatment Market by Type (IBS with Diarrhea, IBS with Constipation, and Mixed IBS, Product, and End User : Global Opportunity Analysis and Industry Forecast, 2019-2026

出版商 Allied Market Research 商品編碼 927308
出版日期 內容資訊 英文 250 Pages
商品交期: 2-3個工作天內
價格
全球大腸激躁症治療藥市場:各類型(腹瀉型,便秘型,混合型),各產品,各終端用戶—市場機會分析與業界預測(2019年 ̄2026年) Irritable Bowel Syndrome Treatment Market by Type (IBS with Diarrhea, IBS with Constipation, and Mixed IBS, Product, and End User : Global Opportunity Analysis and Industry Forecast, 2019-2026
出版日期: 2020年01月01日內容資訊: 英文 250 Pages
簡介

大腸激躁症(IBS)是由於結腸的肌肉收縮引起的胃腸道疾病,主要影響大腸。IBS與腸道功能障礙有關,在老年人中更為常見。常見症狀包括腹瀉,便秘,腸功能改變和不適,腹脹和腹痛,內鏡檢查和血液檢查可用於診斷。IBS分為三種類型:腹瀉型(IBS-D),便秘型(IBS-C)和混合型(IBS-M),治療方法包括醫藥品的給藥,飲食習慣的改善,壓力緩和,諮詢等。IBS治療藥市場規模在2018年時達到10億7,100萬美元,2026年將擴大到20億1,200萬美元,2019年∼2026年間年複合成長率將為8.2%。

本報告提供全球IBS治療藥市場調查,提供市場概要,疾病的各類型,各產品,各終端用戶,各地區的市場分析,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 報告概要
  • 利害關係者的主要優點
  • 主要市場區隔
  • 調查手法
    • 2次調查
    • 1次調查
    • 分析師的工具和模式

第2章 摘要整理

  • 主要調查結果
  • Cxo的見解

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
    • 主要的投資品牌
  • 波特的五力分析
  • 市場動態
    • 成長促進因素
    • 成長阻礙因素
    • 市場機會
    • 影響分析

第4章 市場分析:各類型

  • 概要
    • 市場規模與預測
  • 腹瀉型(IBS-D)
    • 市場主要趨勢,成長要素,機會
    • 市場規模與預測
    • 市場分析:各國
  • 便秘型(IBS-C)
  • 混合型(IBS-M)

第5章 市場分析:各產品

  • 概要
    • 市場規模與預測
  • Rifaximin
  • Eluxadoline
  • Lubiprostone
  • Linaclotide
  • 其他

第6章 市場分析:各終端用戶

  • 概要
    • 市場規模與預測
  • 醫院內的藥局
  • 藥妝店與零售藥局
  • 線上藥局

第7章 市場分析:各地區

  • 概要
    • 市場規模與預測
  • 北美
  • 歐洲
  • 亞太地區
  • 南美·中東·非洲

第8章 企業簡介

  • Abbott Laboratories
  • Allergan Plc
  • Ardelyx Inc.
  • Astellas Pharma Inc.
  • Astrazeneca Plc
  • Glaxosmithkline Plc
  • Johnson & Johnson (Mcneil Consumer Healthcare)
  • Novartis Ag
  • Sebela Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Ltd.
目錄
Product Code: LI_206313

The irritable bowel syndrome treatment market was valued at $1,071 million in 2018, and is estimated to reach at $2,012 million by 2026, registering a CAGR of 8.2% from 2019 to 2026.

Irritable bowel syndrome is a gastrointestinal disorder of gut that may be identified by colon muscle contraction. It majorly affects the large intestine. In addition, it is associated with the malfunction of the bowel, and majorly occurs in geriatric population. Diarrhea, constipation, alteration & discomfort in bowel function, bloating, and abdominal pain are some of the common symptoms of irritable bowel syndrome. Endoscopy and blood test are normally performed to detect this irritable bowel syndrome. Irritable bowel syndrome is classified into three types such as IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and mixed IBS. Treatment of irritable bowel syndrome include proper medicines, change in diet, stress relief, and counseling. Medicines used in the treatment of irritable bowel syndrome include rifaximin, eluxadoline, lubiprostone, linaclotide, and others.

Significant increase in prevalence of gastrointestinal diseases and disorders such as alteration of bowel habit, abdominal pain, adoption of sedentary lifestyle, increase in level of stress, and unhealthy diet are the key factors that fuel the growth of the irritable bowel syndrome treatment market. According to the International Foundation for Gastrointestinal Disorders (IFFGD), it was estimated that irritable bowel syndrome affects around 25-45 million in the U.S. in 2016. Moreover, company developing products with symptom specific application and subsequent launches, increase in geriatric population, and rise in awareness programs for irritable bowel syndrome treatment are other factors that contribute toward the growth of the market. Furthermore, rise in prevalence of irritable bowel syndrome in female is expected to further boost the growth of global irritable bowel treatment market during the forecast period. However, high competition among the key players related to pricing and lack of specific treatment which treat all the symptoms of this disorder are expected to hinder the growth of the market.

The irritable bowel syndrome treatment market is segmented into type, product, end user, and region. Depending on type, the market is categorized into IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and Mixed IBS. On the basis of product, the market is classified into rifaximin, eluxadoline, lubiprostone, linaclotide, and others. On the basis of end user, the market is divided into hospitals pharmacies, drug stores & retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Type

  • IBS with Diarrhea (IBS-D)
  • IBS with Constipation (IBS-C)
  • Mixed IBS

By Product

  • Rifaximin
  • Eluxadoline
  • Lubiprostone
  • Linaclotide
  • Others

By End User

  • Hospitals Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
  • LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Abbott Laboratories
  • Allergan plc
  • Ardelyx Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • GlaxoSmithKline Plc
  • Johnson & Johnson (McNeil Consumer Healthcare)
  • Novartis AG
  • Sebela Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Ltd.
  • LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
  • Bausch Health
  • Synthetic Biologics, Inc.
  • Callisto Pharmaceuticals, Inc. (Synergy Pharmaceuticals)
  • Ironwood Pharmaceuticals, Inc.
  • Lexicon Pharmaceuticals, Inc.

Table of Contents

Chapter 1: Introduction

  • 1.1. Report Description
  • 1.2. Key Benefits For Stakeholders
  • 1.3. Key Market Segments
  • 1.4. Research Methodology
    • 1.4.1. Secondary Research
    • 1.4.2. Primary Research
    • 1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary

  • 2.1. Key Findings of The Study
  • 2.2. Cxo Perspective

Chapter 3: Market Overview

  • 3.1. Market Definition And Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
  • 3.3. Porter'S Five Force Analysis
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise In Geriatric Population
      • 3.4.1.2. Rise In Prevalence of Gastrointestinal Disorders
      • 3.4.1.3. Increase In Number of Pipeline Drugs
    • 3.4.2. Restrains
      • 3.4.2.1. Poor Demand In Under Developed Countries
    • 3.4.3. Opportunities
      • 3.4.3.1. Untapped Opportunities In Developing Economies
    • 3.4.4. Impact Analysis

Chapter 4: Irritable Bowel Syndrome Treatment Market, By Type

  • 4.1. Overview
    • 4.1.1. Market Size And Forecast
  • 4.2. Ibs With Diarrhea (Ibs-D)
    • 4.2.1. Key Market Trends, Growth Factors, And Opportunities
    • 4.2.2. Market Size And Forecast
    • 4.2.3. Market Analysis, By Country
  • 4.3. Ibs With Constipation (Ibs-C)
    • 4.3.1. Key Market Trends, Growth Factors, And Opportunities
    • 4.3.2. Market Size And Forecast, By Region
    • 4.3.3. Market Analysis, By Country
  • 4.4. Mixed-Presentation Ibs (Ibs-M)
    • 4.4.1. Key Market Trends, Growth Factors, And Opportunities
    • 4.4.2. Market Size And Forecast
    • 4.4.3. Market Analysis, By Country

Chapter 5: Irritable Bowel Syndrome Treatment Market, By Product

  • 5.1. Overview
    • 5.1.1. Market Size And Forecast
  • 5.2. Rifaximin
    • 5.2.1. Market Size And Forecast
    • 5.2.2. Market Analysis, By Country
  • 5.3. Eluxadoline
    • 5.3.1. Market Size And Forecast
    • 5.3.2. Market Analysis, By Country
  • 5.4. Lubiprostone
    • 5.4.1. Market Size And Forecast
    • 5.4.2. Market Analysis, By Country
  • 5.5. Linaclotide
    • 5.5.1. Market Size And Forecast
    • 5.5.2. Market Analysis, By Country
  • 5.6. Others
    • 5.6.1. Market Size And Forecast
    • 5.6.2. Market Analysis, By Country

Chapter 6: Irritable Bowel Syndrome Treatment Market, By End User

  • 6.1. Overview
    • 6.1.1. Market Size And Forecast
  • 6.2. Hospitals Pharmacies
    • 6.2.1. Market Size And Forecast
    • 6.2.2. Market Analysis, By Country
  • 6.3. Drug Stores And Retail Pharmacies
    • 6.3.1. Market Size And Forecast
    • 6.3.2. Market Analysis, By Country
  • 6.4. Online Pharmacies
    • 6.4.1. Market Size And Forecast
    • 6.4.2. Market Analysis, By Country

Chapter 7: Irritable Bowel Syndrome Treatment Market, By Region

  • 7.1. Overview
    • 7.1.1. Market Size And Forecast
  • 7.2. North America
    • 7.2.1. Key Market Trends, Growth Factors, And Opportunities
    • 7.2.2. Market Size And Forecast, By Country
      • 7.2.2.1. U.S.
      • 7.2.2.1.1. U.S. Irritable Bowel Syndrome Treatment Market, By Type
      • 7.2.2.1.2. U.S. Irritable Bowel Syndrome Treatment Market, By Product
      • 7.2.2.1.3. U.S. Irritable Bowel Syndrome Treatment Market, By End User
      • 7.2.2.2. Canada
      • 7.2.2.2.1. Canada Irritable Bowel Syndrome Treatment Market, By Type
      • 7.2.2.2.2. Canada Irritable Bowel Syndrome Treatment Market, By Product
      • 7.2.2.2.3. Canada Irritable Bowel Syndrome Treatment Market, By End User
      • 7.2.2.3. Mexico
      • 7.2.2.3.1. Mexico Irritable Bowel Syndrome Treatment Market, By Type
      • 7.2.2.3.2. Mexico Irritable Bowel Syndrome Treatment Market, By Product
      • 7.2.2.3.3. Mexico Irritable Bowel Syndrome Treatment Market, By End User
    • 7.2.3. North America Market Size And Forecast, By Type
    • 7.2.4. North America Market Size And Forecast, By Product
    • 7.2.5. North America Market Size And Forecast, By End User
  • 7.3. Europe
    • 7.3.1. Key Market Trends, Growth Factors, And Opportunities
    • 7.3.2. Market Size And Forecast, By Country
      • 7.3.2.1. Germany
      • 7.3.2.1.1. Germany Irritable Bowel Syndrome Treatment Market, By Type
      • 7.3.2.1.2. Germany Irritable Bowel Syndrome Treatment Market, By Product
      • 7.3.2.1.3. Germany Irritable Bowel Syndrome Treatment Market, By End User
      • 7.3.2.2. France
      • 7.3.2.2.1. France Irritable Bowel Syndrome Treatment Market, By Type
      • 7.3.2.2.2. France Irritable Bowel Syndrome Treatment Market, By Product
      • 7.3.2.2.3. France Irritable Bowel Syndrome Treatment Market, By End User
      • 7.3.2.3. Uk
      • 7.3.2.3.1. Uk Irritable Bowel Syndrome Treatment Market, By Type
      • 7.3.2.3.2. Uk Irritable Bowel Syndrome Treatment Market, By Product
      • 7.3.2.3.3. Uk Irritable Bowel Syndrome Treatment Market, By End User
      • 7.3.2.4. Italy
      • 7.3.2.4.1. Italy Irritable Bowel Syndrome Treatment Market, By Type
      • 7.3.2.4.2. Italy Irritable Bowel Syndrome Treatment Market, By Product
      • 7.3.2.4.3. Italy Irritable Bowel Syndrome Treatment Market, By End User
      • 7.3.2.5. Spain
      • 7.3.2.5.1. Spain Irritable Bowel Syndrome Treatment Market, By Type
      • 7.3.2.5.2. Spain Irritable Bowel Syndrome Treatment Market, By Product
      • 7.3.2.5.3. Spain Irritable Bowel Syndrome Treatment Market, By End User
      • 7.3.2.6. Rest of Europe
      • 7.3.2.6.1. Rest of Europe Irritable Bowel Syndrome Treatment Market, By Type
      • 7.3.2.6.2. Rest of Europe Irritable Bowel Syndrome Treatment Market, By Product
      • 7.3.2.6.3. Rest of Europe Irritable Bowel Syndrome Treatment Market, By End User
    • 7.3.3. Europe Market Size And Forecast, By Type
    • 7.3.4. Europe Market Size And Forecast, By Product
    • 7.3.5. Europe Market Size And Forecast, By End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends, Growth Factors, And Opportunities
    • 7.4.2. Market Size And Forecast, By Country
      • 7.4.2.1. Japan
      • 7.4.2.1.1. Japan Irritable Bowel Syndrome Treatment Market, By Type
      • 7.4.2.1.2. Japan Irritable Bowel Syndrome Treatment Market, By Product
      • 7.4.2.1.3. Japan Irritable Bowel Syndrome Treatment Market, By End User
      • 7.4.2.2. China
      • 7.4.2.2.1. China Irritable Bowel Syndrome Treatment Market, By Type
      • 7.4.2.2.2. China Irritable Bowel Syndrome Treatment Market, By Product
      • 7.4.2.2.3. China Irritable Bowel Syndrome Treatment Market, By End User
      • 7.4.2.3. Australia
      • 7.4.2.3.1. Australia Irritable Bowel Syndrome Treatment Market, By Type
      • 7.4.2.3.2. Australia Irritable Bowel Syndrome Treatment Market, By Product
      • 7.4.2.3.3. Australia Irritable Bowel Syndrome Treatment Market, By End User
      • 7.4.2.4. India
      • 7.4.2.4.1. India Irritable Bowel Syndrome Treatment Market, By Type
      • 7.4.2.4.2. India Irritable Bowel Syndrome Treatment Market, By Product
      • 7.4.2.4.3. India Irritable Bowel Syndrome Treatment Market, By End User
      • 7.4.2.5. South Korea
      • 7.4.2.5.1. South Korea Irritable Bowel Syndrome Treatment Market, By Type
      • 7.4.2.5.2. South Korea Irritable Bowel Syndrome Treatment Market, By Product
      • 7.4.2.5.3. South Korea Irritable Bowel Syndrome Treatment Market, By End User
      • 7.4.2.6. Rest of Asia-Pacific
      • 7.4.2.6.1. Rest of Asia-Pacific Irritable Bowel Syndrome Treatment Market, By Type
      • 7.4.2.6.2. Rest of Asia-Pacific Irritable Bowel Syndrome Treatment Market, By Product
      • 7.4.2.6.3. Rest of Asia-Pacific Irritable Bowel Syndrome Treatment Market, By End User
    • 7.4.3. Asia-Pacific Market Size And Forecast, By Type
    • 7.4.4. Asia-Pacific Market Size And Forecast, By Product
    • 7.4.5. Asia-Pacific Market Size And Forecast, By End User
  • 7.5. Lamea
    • 7.5.1. Key Market Trends, Growth Factors, And Opportunities
    • 7.5.2. Market Size And Forecast, By Country
      • 7.5.2.1. Brazil
      • 7.5.2.1.1. Brazil Irritable Bowel Syndrome Treatment Market, By Type
      • 7.5.2.1.2. Brazil Irritable Bowel Syndrome Treatment Market, By Product
      • 7.5.2.1.3. Brazil Irritable Bowel Syndrome Treatment Market, By End User
      • 7.5.2.2. Saudi Arabia
      • 7.5.2.2.1. Saudi Arabia Irritable Bowel Syndrome Treatment Market, By Type
      • 7.5.2.2.2. Saudi Arabia Irritable Bowel Syndrome Treatment Market, By Product
      • 7.5.2.2.3. Saudi Arabia Irritable Bowel Syndrome Treatment Market, By End User
      • 7.5.2.3. South Africa
      • 7.5.2.3.1. South Africa Irritable Bowel Syndrome Treatment Market, By Type
      • 7.5.2.3.2. South Africa Irritable Bowel Syndrome Treatment Market, By Product
      • 7.5.2.3.3. South Africa Irritable Bowel Syndrome Treatment Market, By End User
      • 7.5.2.4. Rest of Lamea
      • 7.5.2.4.1. Rest of Lamea Irritable Bowel Syndrome Treatment Market, By Type
      • 7.5.2.4.2. Rest of Lamea Irritable Bowel Syndrome Treatment Market, By Product
      • 7.5.2.4.3. Rest of Lamea Irritable Bowel Syndrome Treatment Market, By End User
    • 7.5.3. Lamea Market Size And Forecast, By Type
    • 7.5.4. Lamea Market Size And Forecast, By Product
    • 7.5.5. Lamea Market Size And Forecast, By End User

Chapter 8: Company Profiles

  • 8.1. Abbott Laboratories
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Operating Business Segments
    • 8.1.4. Product Portfolio
    • 8.1.5. Business Performance
  • 8.2. Allergan Plc
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Operating Business Segments
    • 8.2.4. Product Portfolio
    • 8.2.5. Business Performance
    • 8.2.6. Key Strategic Moves And Developments
  • 8.3. Ardelyx Inc.
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Operating Business Segments
    • 8.3.4. Product Portfolio
    • 8.3.5. Business Performance
    • 8.3.6. Key Strategic Moves And Developments
  • 8.4. Astellas Pharma Inc.
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Operating Business Segments
    • 8.4.4. Product Portfolio
    • 8.4.5. Business Performance
    • 8.4.6. Key Strategic Moves And Developments
  • 8.5. Astrazeneca Plc
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Operating Business Segments
    • 8.5.4. Product Portfolio
    • 8.5.5. Business Performance
    • 8.5.6. Key Strategic Moves And Developments
  • 8.6. Glaxosmithkline Plc
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Operating Business Segments
    • 8.6.4. Product Portfolio
    • 8.6.5. Business Performance
  • 8.7. Johnson & Johnson (Mcneil Consumer Healthcare)
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Operating Business Segments
    • 8.7.4. Product Portfolio
    • 8.7.5. Business Performance
  • 8.8. Novartis Ag
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Operating Business Segments
    • 8.8.4. Product Portfolio
    • 8.8.5. Business Performance
    • 8.8.6. Key Strategic Moves And Developments
  • 8.9. Sebela Pharmaceuticals Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Operating Business Segments
    • 8.9.4. Product Portfolio
  • 8.10. Takeda Pharmaceutical Company Ltd.
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Operating Business Segments
    • 8.10.4. Product Portfolio
    • 8.10.5. Business Performance

List of Tables

  • Table 01. Global Irritable Bowel Syndrome Treatment Market, By Type, 2018-2026 ($Million)
  • Table 02. Ibs With Diarrhea Irritable Bowel Syndrome Treatment Market, By Region, 2018-2026 ($Million)
  • Table 03. Ibs With Constipation Irritable Bowel Syndrome Treatment Market, By Region, (2018-2026 ($Million)
  • Table 04. Mixed Ibs Irritable Bowel Syndrome Treatment Market, By Region, 2018-2026 ($Million)
  • Table 05. Global Irritable Bowel Syndrome Treatment Market, By Product, 2018-2026 ($Million)
  • Table 06. Rifaximin Irritable Bowel Syndrome Treatment Market, By Region, 2018-2026 ($Million)
  • Table 07. Eluxadoline Irritable Bowel Syndrome Treatment Market, By Region, 2018-2026 ($Million)
  • Table 08. Lubiprostone Irritable Bowel Syndrome Treatment Market, By Region, 2018-2026 ($Million)
  • Table 09. Linaclotide Irritable Bowel Syndrome Treatment Market, By Region, 2018-2026 ($Million)
  • Table 10. Others Global Irritable Bowel Syndrome Treatment Market, By Region, 2018-2026 ($Million)
  • Table 11. Global Irritable Bowel Syndrome Treatment Market, By End User, 2018-2026 ($Million)
  • Table 12. Irritable Bowel Syndrome Treatment Market For Hospitals Pharmacies, By Region, 2018-2026 ($Million)
  • Table 13. Irritable Bowel Syndrome Treatment Market For Drug Stores And Retail Pharmacies, By Region, 2018-2026 ($Million)
  • Table 14. Irritable Bowel Syndrome Treatment Market For Online Pharmacies, By Region, 2018-2026 ($Million)
  • Table 15. Irritable Bowel Syndrome Treatment Market, By Region, 2018-2026 ($Million)
  • Table 16. North America Irritable Bowel Syndrome Treatment Market, By Country, 2018-2026 ($Million)
  • Table 17. U.S. Irritable Bowel Syndrome Treatment Market, By Type, 2018-2026
  • Table 18. U.S. Irritable Bowel Syndrome Treatment Market, By Product, 2018-2026
  • Table 19. U.S. Irritable Bowel Syndrome Treatment Market, By End User, 2018-2026
  • Table 20. Canada Irritable Bowel Syndrome Treatment Market, By Type, 2018-2026
  • Table 21. Canada Irritable Bowel Syndrome Treatment Market, By Product, 2018-2026
  • Table 22. Canada Irritable Bowel Syndrome Treatment Market, By End User, 2018-2026
  • Table 23. Mexico Irritable Bowel Syndrome Treatment Market, By Type, 2018-2026
  • Table 24. Mexico Irritable Bowel Syndrome Treatment Market, By Product, 2018-2026
  • Table 25. Mexico Irritable Bowel Syndrome Treatment Market, By End User, 2018-2026
  • Table 26. North America Irritable Bowel Syndrome Treatment Market, By Type, 2018-2026
  • Table 27. North America Irritable Bowel Syndrome Treatment Market, By Product, 2018-2026
  • Table 28. North America Irritable Bowel Syndrome Treatment Market, By End User, 2018-2026
  • Table 29. Europe Irritable Bowel Syndrome Treatment Market, By Country, 2018-2026 ($Million)
  • Table 30. Germany Irritable Bowel Syndrome Treatment Market, By Type, 2018-2026
  • Table 31. Germany Irritable Bowel Syndrome Treatment Market, By Product, 2018-2026
  • Table 32. Germany Irritable Bowel Syndrome Treatment Market, By End User, 2018-2026
  • Table 33. France Irritable Bowel Syndrome Treatment Market, By Type, 2018-2026
  • Table 34. France Irritable Bowel Syndrome Treatment Market, By Product, 2018-2026
  • Table 35. France Irritable Bowel Syndrome Treatment Market, By End User, 2018-2026
  • Table 36. Uk Irritable Bowel Syndrome Treatment Market, By Type, 2018-2026
  • Table 37. Uk Irritable Bowel Syndrome Treatment Market, By Product, 2018-2026
  • Table 38. Uk Irritable Bowel Syndrome Treatment Market, By End User, 2018-2026
  • Table 39. Italy Irritable Bowel Syndrome Treatment Market, By Type, 2018-2026
  • Table 40. Italy Irritable Bowel Syndrome Treatment Market, By Product, 2018-2026
  • Table 41. Italy Irritable Bowel Syndrome Treatment Market, By End User, 2018-2026
  • Table 42. Spain Irritable Bowel Syndrome Treatment Market, By Type, 2018-2026
  • Table 43. Spain Irritable Bowel Syndrome Treatment Market, By Product, 2018-2026
  • Table 44. Spain Irritable Bowel Syndrome Treatment Market, By End User, 2018-2026
  • Table 45. Rest of Europe Irritable Bowel Syndrome Treatment Market, By Type, 2018-2026
  • Table 46. Rest of Europe Irritable Bowel Syndrome Treatment Market, By Product, 2018-2026
  • Table 47. Rest of Europe Irritable Bowel Syndrome Treatment Market, By End User, 2018-2026
  • Table 48. Europe Irritable Bowel Syndrome Treatment Market, By Type, 2018-2026
  • Table 49. Europe Irritable Bowel Syndrome Treatment Market, By Product, 2018-2026
  • Table 50. Europe Irritable Bowel Syndrome Treatment Market, By End User, 2018-2026
  • Table 51. Asia-Pacific Irritable Bowel Syndrome Treatment Market, By Country, 2018-2026 ($Million)
  • Table 52. Japan Irritable Bowel Syndrome Treatment Market, By Product, 2018-2026
  • Table 53. Japan Irritable Bowel Syndrome Treatment Market, By Product, 2018-2026
  • Table 54. Japan Irritable Bowel Syndrome Treatment Market, By End User, 2018-2026
  • Table 55. China Irritable Bowel Syndrome Treatment Market, By Type, 2018-2026
  • Table 56. China Irritable Bowel Syndrome Treatment Market, By Product, 2018-2026
  • Table 57. China Irritable Bowel Syndrome Treatment Market, By End User, 2018-2026
  • Table 58. Australia Irritable Bowel Syndrome Treatment Market, By Type, 2018-2026
  • Table 59. Australia Irritable Bowel Syndrome Treatment Market, By Product, 2018-2026
  • Table 60. Australia Irritable Bowel Syndrome Treatment Market, By End User, 2018-2026
  • Table 61. India Irritable Bowel Syndrome Treatment Market, By Type, 2018-2026
  • Table 62. India Irritable Bowel Syndrome Treatment Market, By Product, 2018-2026
  • Table 63. India Irritable Bowel Syndrome Treatment Market, By End User, 2018-2026
  • Table 64. South Korea Irritable Bowel Syndrome Treatment Market, By Type, 2018-2026
  • Table 65. South Korea Irritable Bowel Syndrome Treatment Market, By Product, 2018-2026
  • Table 66. South Korea Irritable Bowel Syndrome Treatment Market, By End User, 2018-2026
  • Table 67. Rest of Asia-Pacific Irritable Bowel Syndrome Treatment Market, By Type, 2018-2026
  • Table 68. Rest of Asia-Pacific Irritable Bowel Syndrome Treatment Market, By Product, 2018-2026
  • Table 69. Rest of Asia-Pacific Irritable Bowel Syndrome Treatment Market, By End User, 2018-2026
  • Table 70. Asia-Pacific Irritable Bowel Syndrome Treatment Market, By Type, 2018-2026
  • Table 71. Asia-Pacific Irritable Bowel Syndrome Treatment Market, By Product, 2018-2026
  • Table 72. Asia-Pacific Irritable Bowel Syndrome Treatment Market, By End User, 2018-2026
  • Table 73. Lamea Irritable Bowel Syndrome Treatment Market, By Country, 2018-2026 ($Million)
  • Table 74. Brazil Irritable Bowel Syndrome Treatment Market, By Type, 2018-2026
  • Table 75. Brazil Irritable Bowel Syndrome Treatment Market, By Product, 2018-2026
  • Table 76. Brazil Irritable Bowel Syndrome Treatment Market, By End User, 2018-2026
  • Table 77. Saudi Arabia Irritable Bowel Syndrome Treatment Market, By Type, 2018-2026
  • Table 78. Saudi Arabia Irritable Bowel Syndrome Treatment Market, By Product, 2018-2026
  • Table 79. Saudi Arabia Irritable Bowel Syndrome Treatment Market, By End User, 2018-2026
  • Table 80. South Africa Irritable Bowel Syndrome Treatment Market, By Type, 2018-2026
  • Table 81. South Africa Irritable Bowel Syndrome Treatment Market, By Product, 2018-2026
  • Table 82. South Africa Irritable Bowel Syndrome Treatment Market, By End User, 2018-2026
  • Table 83. Rest of Lamea Irritable Bowel Syndrome Treatment Market, By Type, 2018-2026
  • Table 84. Rest of Lamea Irritable Bowel Syndrome Treatment Market, By Product, 2018-2026
  • Table 85. Rest of Lamea Irritable Bowel Syndrome Treatment Market, By End User, 2018-2026
  • Table 86. Lamea Irritable Bowel Syndrome Treatment Market, By Type, 2018-2026
  • Table 87. Lamea Irritable Bowel Syndrome Treatment Market, By Product, 2018-2026
  • Table 88. Lamea Irritable Bowel Syndrome Treatment Market, By End User, 2018-2026
  • Table 89. Abbott: Company Snapshot
  • Table 90. Abbott: Operating Segments
  • Table 91. Abbott: Product Portfolio
  • Table 92. Allergan: Company Snapshot
  • Table 93. Allergan: Operating Segments
  • Table 94. Allergan: Product Portfolio
  • Table 95. Ardelyx: Company Snapshot
  • Table 96. Ardelyx: Product Portfolio
  • Table 97. Astellas: Company Snapshot
  • Table 98. Astellas: Product Portfolio
  • Table 99. Astrazeneca: Company Snapshot
  • Table 100. Astrazeneca: Operating Segments
  • Table 101. Astrazeneca: Product Portfolio
  • Table 102. Gsk: Company Snapshot
  • Table 103. Gsk: Operating Segments
  • Table 104. Gsk: Product Portfolio
  • Table 105. J&J: Company Snapshot
  • Table 106. J&J: Operating Segments
  • Table 107. J&J: Product Portfolio
  • Table 108. Novartis: Company Snapshot
  • Table 109. Novartis: Operating Segments
  • Table 110. Novartis: Product Portfolio
  • Table 111. Sebela: Company Snapshot
  • Table 112. Sebela: Product Portfolio
  • Table 113. Takeda: Company Snapshot
  • Table 114. Takeda: Product Portfolio

List of Figures

  • Figure 01. Global Irritable Bowel Syndrome Treatment Market Segmentation
  • Figure 02. Top Investment Pockets
  • Figure 03. Moderate Bargaining Power of Suppliers
  • Figure 04. Moderate Bargaining Power of Buyers
  • Figure 05. Moderate Threat of Substitutes
  • Figure 06. Low Threat of New Entrants
  • Figure 07. Moderate Intensity of Rivalry
  • Figure 08. Impact Analysis
  • Figure 09. Comparative Analysis of Ibs With Diarrhea Irritable Bowel Syndrome Treatment Market, By Country, 2018 & 2026 ($Million)
  • Figure 10. Comparative Analysis of Ibs With Constipation Irritable Bowel Syndrome Treatment Market, By Country, 2018 & 2026 ($Million)
  • Figure 11. Comparative Analysis of Mixed Ibs Irritable Bowel Syndrome Treatment Market, By Country, 2018 & 2026 ($Million)
  • Figure 12. Comparative Analysis of Rifaximin Irritable Bowel Syndrome Treatment Market, By Country, 2018 & 2026 ($Million)
  • Figure 13. Comparative Analysis of Eluxadoline Irritable Bowel Syndrome Treatment Market, By Country, 2018 & 2026 ($Million)
  • Figure 14. Comparative Analysis of Lubiprostone Irritable Bowel Syndrome Treatment Market, By Country, 2018 & 2026 ($Million)
  • Figure 15. Comparative Analysis of Linaclotide Irritable Bowel Syndrome Treatment Market, By Country, 2018 & 2026 ($Million)
  • Figure 16. Comparative Analysis of Others Irritable Bowel Syndrome Treatment Market, By Country, 2018 & 2026 ($Million)
  • Figure 17. Comparative Analysis of Irritable Bowel Syndrome Treatment Market For Hospitals Pharmacies, By Country, 2018 & 2026 ($Million)
  • Figure 18. Comparative Analysis of Irritable Bowel Syndrome Treatment Market For Drug Stores And Retail Pharmacies, By Country, 2018 & 2026 ($Million)
  • Figure 19. Comparative Analysis of Irritable Bowel Syndrome Treatment Market For Online Pharmacies, By Country, 2018 & 2026 ($Million)
  • Figure 20. Abbott: Net Sales, 2016-2018 ($Million)
  • Figure 21. Abbott: Revenue Share By Segment, 2018 (%)
  • Figure 22. Abbott: Revenue Share By Region, 2018 (%)
  • Figure 23. Allergan: Net Sales, 2016-2018 ($Million)
  • Figure 24. Allergan: Revenue Share By Segment, 2018 (%)
  • Figure 25. Ardelyx: Net Sales, 2017-2018 ($Million)
  • Figure 26. Ardelyx: Revenue Share By Region, 2018 (%)
  • Figure 27. Astellas: Net Sales, 2016-2018 ($Million)
  • Figure 28. Astellas: Revenue Share By Segment, 2018 (%)
  • Figure 29. Astellas: Revenue Share By Region, 2018 (%)
  • Figure 30. Astrazeneca: Net Sales, 2016-2018 ($Million)
  • Figure 31. Astrazeneca: Revenue Share By Segment, 2018 (%)
  • Figure 32. Astrazeneca: Revenue Share By Region, 2018 (%)
  • Figure 33. Gsk: Net Sales, 2016-2018 ($Million)
  • Figure 34. Gsk: Revenue Share By Segment, 2018 (%)
  • Figure 35. Gsk: Revenue Share By Region, 2018 (%)
  • Figure 36. J&J: Net Sales, 2016-2018 ($Million)
  • Figure 37. J&J: Revenue Share By Segment, 2018 (%)
  • Figure 38. J&J: Revenue Share By Region, 2018 (%)
  • Figure 39. Novartis: Net Sales, 2016-2018 ($Million)
  • Figure 40. Novartis: Revenue Share By Segment, 2018 (%)
  • Figure 41. Novartis: Revenue Share By Region, 2018 (%)
  • Figure 42. Takeda: Net Sales, 2016-2018 ($Million)
  • Figure 43. Takeda: Revenue Share By Region, 2018 (%)